Drug Research

Myriad Genetics, Inc. , a leader in molecular diagnostics and personalized medicine, announced that AstraZeneca will use the Company’s myChoice® HRD Plus in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment...

NexImmune, an emerging leader in the field of antigen-directed immunotherapy, announced the closing of a Series A financing co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital, along with significant participation from Piedmont Capital Partners. ...

Idorsia Ltd announced that it has entered into a research collaboration that provides Roche with an exclusive option right to develop and market first-in-class compounds for a promising new approach in the field of cancer immunotherapy. ...

NorthSea Therapeutics B.V. , a newly established Dutch biotech company, announced the completion of a €25m Series A funding for the development of icosabutate, a structurally engineered fatty acid (‘SEFA’) as a novel, oral approach for the treatment of...

Agendia, a world leader in personalized medicine and molecular cancer diagnostics, and Institute Curie in Paris, France, a leading player in the fight against cancer. Announce a co-validation partnership for Agendia’s new in vitro diagnostic (IVD)...

Torque, an immuno-oncology company developing Deep Primed cell therapies that direct and evoke immune responses in the tumor microenvironment, announced the launch of its technology platform to create a new class of immune cell therapeutics to treat cancer, financed...

Eisai Co., Ltd. has announced that its German sales company Eisai GmbH and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) have agreed on a reimbursement price for Eisai's antiepileptic drug (AED) Fycompa (perampanel).  As...